FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer
Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects, good and/or bad, of the drug
regorafenib with chemotherapy regime (FOLFOX). This is a a Phase II trial that will study if
this new treatment is effective and safe in patients with esophagus and stomach cancer.